SEP 9, 2026 · PHASE 2 TRIAL
Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer
ClinicalTrials.gov
This is a clinical trial registry record for a planned Phase 2 study with no results posted; it describes the protocol and enrollment target only.
Reported
Planned enrollment40
Primary outcome measureProgression-free survival, up to 2 years
Study phasePhase 2